What antitrust challenge? Illumina completes $8B Grail buyout while FTC, EU probes remain ongoing

Max Gelman

Senior Editor

In defiance of FTC and EU scrutiny, Illumina said Wednesday it has completed its multibillion dollar acquisition of Grail, setting off what’s likely to be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

What antitrust challenge? Illumina completes $8B Grail buyout while FTC, EU probes remain ongoing

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump says he'll sign order on 'most favored nation' drug price plans Monday

Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

What an­titrust chal­lenge? Il­lu­mi­na com­pletes $8B Grail buy­out while FTC, EU probes re­main on­go­ing

Senior Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

What antitrust challenge? Illumina completes $8B Grail buyout while FTC, EU probes remain ongoing